These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30300440)

  • 21. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
    Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
    Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
    Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antibiotic arms race: current and emerging therapy for
    Plazak ME; Tamma PD; Heil EL
    Expert Opin Pharmacother; 2018 Dec; 19(18):2019-2031. PubMed ID: 30346216
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.
    Castanheira M; Rhomberg PR; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an
    Sabet M; Tarazi Z; Rubio-Aparicio D; Nolan TG; Parkinson J; Lomovskaya O; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
    Fergadaki S; Renieris G; Machairas N; Sabracos L; Droggiti DI; Misiakos E; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2021 Sep; 58(3):106384. PubMed ID: 34161789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China.
    Zhou M; Yang Q; Lomovskaya O; Sun D; Kudinha T; Xu Z; Zhang G; Chen X; Xu Y
    J Antimicrob Chemother; 2018 Oct; 73(10):2789-2796. PubMed ID: 29982437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
    Dhillon S
    Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination.
    Cho JC; Zmarlicka MT; Shaeer KM; Pardo J
    Ann Pharmacother; 2018 Aug; 52(8):769-779. PubMed ID: 29514462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.
    Mouloudi E; Protonotariou E; Zagorianou A; Iosifidis E; Karapanagiotou A; Giasnetsova T; Tsioka A; Roilides E; Sofianou D; Gritsi-Gerogianni N
    Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1250-6. PubMed ID: 20973725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report.
    Choi S; Fedorenko M; Lin-Torre J; Mistry N; Smoke S
    Int J Infect Dis; 2022 Sep; 122():1041-1043. PubMed ID: 35932967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Looking beyond ceftazidime-avibactam resistance in KPC-producing
    Boattini M; Bianco G; Iannaccone M; Bondi A; Cavallo R; Costa C
    J Chemother; 2021 Dec; 33(8):598-600. PubMed ID: 33843501
    [No Abstract]   [Full Text] [Related]  

  • 35.
    Sime FB; Pandey S; Karamujic N; Parker S; Alexander E; Loutit J; Durso S; Griffith D; Lipman J; Wallis SC; Roberts JA
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections.
    McCarthy MW; Walsh TJ
    Drugs Today (Barc); 2017 Oct; 53(10):521-530. PubMed ID: 29286054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration.
    Kidd JM; Avery LM; Asempa TE; Nicolau DP; Kuti JL
    Clin Ther; 2018 Feb; 40(2):261-269. PubMed ID: 29290374
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Hackel MA; Lomovskaya O; Dudley MN; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa.
    Iannaccone M; Boattini M; Bianco G; Cavallo R; Costa C
    Int J Antimicrob Agents; 2020 Aug; 56(2):106066. PubMed ID: 32599226
    [No Abstract]   [Full Text] [Related]  

  • 40. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.